Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

Adenocarcinoma of the Rectum Clinical Trial

Official title:

Phase II Study of Preoperative Chemotherapy With Ziv-aflibercept (Zaltrap) Followed by Postoperative Chemotherapy With or Without Ziv-aflibercept (Zaltrap) in Patients With Advanced Resectable Colorectal Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02046538
• Other study ID #: 1309014302
• Secondary ID: 2012-AFL-18
• Status: Withdrawn
• Phase: Phase 2
• First received: January 23, 2014
• Last updated: January 23, 2017
• Start date: February 2014
• Est. completion date: February 2018

Study information

• Verified date: January 2017
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to establish the safety of Zaltrap in patients who undergo pre-operative chemotherapy with Zaltrap. The investigators hypothesize that Zaltrap my impact colorectal cancer growth and metastasis.

Description:

Eligible patients will receive 3 months of chemotherapy consisting of either FOLFOX or FOLFIRI (in the case of liver limited CRC) or FOLFOX (in the case of rectal cancer). The FOLFOX regimen consists of Oxaliplatin, Leucovorin, and 5-FU. The FOLFIRI regimen consists of Irinotecan, Leucovorin, and 5-FU. Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 week's from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.

Following resection, patients will be randomly assigned (1:1) to receive chemotherapy with or without zaltrap for 3 additional months. Patients assigned to Zaltrap may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months. Patients will have research blood draws periodically both in the preoperative and postoperative period.

The investigators plan to demonstrate that pre-operative chemotherapy with Zaltrap is not associated with any safety signals that would preclude further drug development in this patient population. The investigators also plan to perform correlative studies to identify potential biomarkers for Zaltrap activity.

The investigators hypothesize that antiangiogenic therapy may specifically target the micrometastatis niche of patients with liver limited metastatic colorectal cancer to significantly increase the chance of cure for these patients.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2018
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have pathologically confirmed adenocarcinoma of the colon or rectum.

• In patients with liver-limited metastatic colorectal cancer, a curative approach is indicated following evaluation by hepatobiliary surgeon as part of multidisciplinary management. Select patients requiring two stage procedure are also eligible following evaluation by hepatobiliary surgeon as part of multidisciplinary management.

• In patients with rectal cancer, primary tumor that is clinically T3-4 or N + (evaluation by colorectal surgery is required as part of multidisciplinary approach).

• No prior chemotherapy for metastatic disease is allowed for patients with CRC-liver mets. (adjuvant FOLFOX is permitted)

• No prior chemotherapy for proximal rectal cancer is allowed

• ECOG Performance status = 2.

• Age >18 years old.

• Patients must have adequate bone marrow, kidney, and liver function as assessed by laboratory parameters.

1. WBC = 3,000/uL

2. Total Bilirubin = 1.5 x upper limits of normal

3. AST (SGOT) = 3 x upper limits of normal

4. ALT (SGPT) = 3 x upper limits of normal

5. Hemoglobin = 9.0 g/dl (without transfusion within 7 d)

6. ANC = 1500 /ml

7. Platelets =100 K/ml (without transfusion)

8. Calculated CrCL > 50 ml/min

• Ability to understand and the willingness to sign a written informed consent document.

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.

Exclusion Criteria:

• Patients with untreated CNS metastases.

• Significant medical co-morbidity that would preclude safe administration of cytotoxic therapy, including but not limited to:

1. Cardiovascular disease

1. Unstable angina

2. Myocardial infarction/ CABG < 3 months prior to study initiation

3. Untreated coronary artery disease

4. NYHA class III or IV heart failure

2. Ongoing serious infection

1. Bacteremia or sepsis requiring intravenous antibiotics

2. HIV with AIDS defining illness

3. Inadequate oral nutritional intake: Requirement for daily intravenous fluids or total parenteral nutrition.

4. Neurological: Stroke = 6 months

5. Psychiatric illness/social situations that would limit compliance with study requirement

• Patients may not receive another investigational agent.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Ziv-aflibercept.

• Pregnant (positive pregnancy test) and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown.

• Major surgical procedure = 4 weeks from starting therapy.

• Grade 3-4 hemorrhage, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulits = 3 months from starting therapy.

• Patients with known DPD deficiency

• Patients with known Gilbert's syndrome

• Patients with = 2g/24 hour urine protein. If urine protein on random UA is = 300 mg/dl, a 24 hour urine protein is not required.

• Symptomatic peripheral sensory neuropathy grade = 2.

• Other malignancy within the last 5 years from study entry, except for basal /squamous cell skin cancer, in situ cervical cancer, or non-metastatic prostate cancer.

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of the Colon
• Adenocarcinoma of the Rectum
• Colorectal Neoplasms
• Rectal Neoplasms

Intervention

Drug:
• Leucovorin
400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
• Oxaliplatin
85 mg/m2 IV over two hours
• 5-FU
400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
• Irinotecan
180 mg/m2 IV over 90 minutes

Locations

Country	Name	City	State
United States	Weill Cornell Medical College	New York city	New York

Sponsors (2)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University	Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse events experienced	Capture the number of adverse events experienced by advanced resectable colorectal cancer subjects treated with pre-operative chemotherapy and Zaltrap	Approximately 24 months per patient
Primary	Number of subjects who demonstrate a response to pre-operative chemotherapy and zaltrap	Capture the number of subjects who demonstrate an improvement (response) in colorectal cancer status after being treated with pre-operative chemotherapy and zaltrap.	Approximately 24 months per patient
Secondary	Survival duration without disease progression	Calculate rate of progression-free survival for subjects following treatment chemotherapy and Zaltrap	2 years per patient